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RESUMEN
Objetivo: El objetivo de esta investigación fue estudiar el efecto del PVP en la disolución in vitro del 
aceclofenaco  en coprecipitados. 
Material y métodos: Se prepararon diferentes coprecipitados de aceclofenaco con distintas cargas 
de droga y se llevaron a cabo los estudios in vitro de disolución de la droga pura, mezclas físicas y 
coprecipitados.
Resultados: Los coprecipitados de aceclofenaco con PVP mostraron un considerable incremento de 
la tasa de disolución en comparación con las mezclas físicas y la droga pura en HCl 0,1 N y tampón 
fosfato con pH 7,4. Los coprecipitados con proporción 1:2  mostraron una tasa máxima de disolución 
en comparación con otras proporciones. La naturaleza amorfa de la droga en coprecipitados fue 
confirmada con microscopia electrónica de barrido así cómo el descenso de la entalpia  de fusión  de 
los coprecipitados  con respecto a la droga pura. Los estudios de espectrometría FT-IR y calorimetría 
diferencial de barrido indicaron que no hubo interacción entre el aceclofenaco y el PVP en estado 
sólido.  La mejora de la disolución se atribuyó al descenso de la cristalinidad y humedad de la 
droga,  la formación del eutéctico y el efecto solubilizante del soporte  de los coprecipitados de 
aceclofenaco.
Conclusión: La disolución del aceclofenaco puede ser mejorada con el uso de los soportes hidrófílicos 
como el PVP.
PALABRAS CLAVE: Aceclofenaco, Disolución, PVP, Biodisponiblidad
ABSTRACT 
Aim: The objective of the present investigation was to study the effect of PVP on in vitro dissolution 
of aceclofenac from coprecipitates. 
Materials and Methods: Aceclofenac coprecipitates (CP) with different drug loadings were prepared 
and in vitro dissolution studies of pure drug, physical mixtures and coprecipitates were carried 
out. 
Results: Coprecipitates of aceclofenac with PVP showed considerable increase in the dissolution 
rate in comparison with physical mixture and pure drug in 0.1 N HCl, pH1.2 and phosphate buffer, 
pH, 7.4. Coprecipitates in 1:2 ratio showed maximum dissolution rate in comparison to other ratios. 
Amorphous nature of the drug in coprecipitates was confirmed by scanning electron microscopy 
and a decrease in enthalpy of drug melting in coprecipitates compared to the pure drug. FT-
IR spectroscopy and differential scanning calorimetry studies indicated no interaction between 
aceclofenac and PVP in coprecipitates in solid state. Dissolution enhancement was attributed to 
decreased crystallinity of the drug and to the wetting, eutectic formation and solubilizing effect of 
the carrier from the coprecipitates of aceclofenac. 
Conclusion: dissolution of aceclofenac can be enhanced by the use of hydrophilic carriers like PVP. 
KEY WORDS: Aceclofenac, Dissolution, PVP, Bioavailability.
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8INTRODUCTION
Up to 40 percent of new chemical entities discovered by 
the pharmaceutical industry today are poorly soluble or 
lipophilic compounds. The solubility issues complicating 
the delivery of these new drugs also affect the delivery 
of many existing drugs1. Poorly water-soluble drugs 
show unpredictable absorption, since their bioavailability 
depends upon dissolution in the gastrointestinal tract. 
The dissolution characteristics of poorly soluble drugs can 
be enhanced by several methods. The solid dispersions 
obtained by the solvent methods are called the co-
precipitates2 .Solid dispersion is one of the effective and 
widely used techniques for dissolution enhancement. 
The increase in dissolution rate for coprecipitates can be 
attributed to a number of factors, which include reduction 
in particle size, absence of agglomeration of fine crystallites 
of the drug, excellent wettability and dispersibility of the 
drug from solid dispersion and partial conversion of the 
drug into amorphous form.
Aceclofenac (AF), 2-[(2,6-dichlorophenyl) amino] benzene 
acetic acid carboxymethyl ester is a new generational 
non-steroidal anti-inflammatory drug showing effective 
anti-inflammatory and analgesic properties and a good 
tolerability profile in a variety of painful conditions 
like ankylosing spondylitis, rheumatoid arthritis and 
osteoarthritis. Aceclofenac is very slightly soluble in 
water3 and therefore an attempt has been made to prepare 
coprecipitates of aceclofenac using hydrophilic carrier 
like polyvinylpyrrolidone (PVP) with an aim to improve 
its extent and rate of dissolution. A particular advantage 
of this carrier for the formation of coprecipitates is having 
good solubility in many organic solvents. Therefore, in the 
present study PVP was chosen as suitable polymers for the 
preparation of coprecipitates. 
MATERIAL AND METhODS
Materials
Aceclofenac was obtained as a gift sample from Ipca Laboratories, 
Mumbai, India. Polyvinylpyrrolidone (PVP); molecular weight: 
29,000 were obtained from Merck (Germany).
Preparation of Coprecipitates and Physical mixtures of 
Aceclofenac
Coprecipitates of AF were prepared with PVP in different 
ratios such as 1:0.5, 1:1 and 1:2 (AF-PVP-CP1, AF-PVP-
CP2 and AF-PVP-CP3) with slow evaporation of ethanolic 
(95%v/v) solutions of drug and carrier in a vacuum oven 
at 40°C. The resulting solid mass was further dried under 
vaccum to a constant weight and stored in dessicator 4. 
The physical mixtures were prepared by mixing pre-
weighed amounts of mesh. No 100-sieve fractions of 
aceclofenac and PVP in the same proportions as used in 
coprecipitates4.
Characterisation 
Percent Yield 
The percent yield of CPs was calculated on the basis of 
dry weight (drug and carriers) and the final weight of CPs 
obtained4.
Average Particle Size 
The CPs were dispersed in liquid paraffin and mounted on 
slides.  Particle size of 200 particles was measured using 
calibrated stage micrometer and ocular micrometer. From 
the data the average particle size was calculated5. 
Wettability Study 
Powdered mixture of CPs (300 mg) was placed in a sintered 
glass funnel with 33 mm internal diameter. The funnel was 
plunged into beaker containing water such that the surface 
of water in the beaker was at the same level as the powder 
or granules in the funnel. Methylene blue powder (10 mg) 
was layered uniformly on the surface of the powder or 
granules in the funnel. The time required for wetting of 
methylene blue powder was measured. The mean of three 
observations was used for drawing the conclusions5.
hygroscopic Studies
One hundred mg each of CPs (w1) was placed on a watch 
glass and exposed to ambient atmospheric conditions 
(70±5% RH, 30±2°C) and saturation humidity conditions 
(99±1% RH, 30±2°C) for 2 days. The substance was weighed 
again (w2).  The gain in the weight was determined and the 
percentage moisture gained was calculated6.
Drug Content 
The CPs (100mg) were accurately weighed and dissolved 
separately in 100ml of 20%v/v acetic acid. The solution 
was suitably diluted and the absorbance was measured at 
275 nm .  Drug content was calculated using the regression 
equation6.
Scanning Electron Microscopy 
Scanning Electron Microscopy (SEM) was carried out for 
1:1 CPs. The surface morphology of the selected binary 
systems was studied using a Phillips 1500, scanning 
electron microscope7.
Fourier Transformed Infrared Spectroscopic Studies 
FTIR spectral studies were carried out for pure drug, 
freshly prepared and six months old 1:1 CPs and individual 
substances to check the compatibility between drug and 
carriers using Shimadzu FTIR-8400S Fourier transform 
infrared spectrophotometer7.  
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9Differential Scanning Calorimetric Studies 
DSC studies were carried out for pure drug, freshly 
prepared and six months old 1:1 CPs. All dynamic DSC 
studies were carried out on a calibrated Shimadzu DSC-
50 Thermal Analyzer. Calorimetric measurements were 
made with empty cell (high purity alpha alumina discs 
as reference). The dynamic scans were taken in nitrogen 
atmosphere at the heating rate of 10°C/minute7.
In Vitro Release Studies 
In vitro release studies were carried out using basket type 
USP XXII dissolution test apparatus (26). Release studies 
were carried separately for pure drug, physical mixtures 
and CPs for 2h in 900 ml of 0.1 N hydrochloric acid solution, 
pH 1.2 and phosphate buffer, pH 7.4 separately, with a 
stirring speed of 50 rpm at a temperature of 37±0.5 °C. Five 
ml aliquots of dissolution medium were withdrawn at an 
interval of 5 minutes for first 15 minutes and then 15 minutes 
intervals, for rest of the two-hour study Absorbance of the 
suitably diluted solutions was measured at 275 nm. The 
drug content was calculated using regression equation5, 6.
Kinetic Analysis of Drug Release
The dissolution profiles of all the CPs were subjected to 
dissolution efficiency and the kinetic analysis to establish 
the drug-release mechanism. The release data were fitted 
to zero order (Equation 1), first order (Equation 2), matrix 
and Hixson-Crowell equations (Equation 3) to ascertain 
the kinetic modeling of drug release8.  
Qt = k0t       (1)
ln Qt = ln Q0 - k1t        (2)
Q01/3 – Qt1/3 = kHCt      (3)
Where Qt  is the amount of drug released at time t, Q0 is 
the initial amount of drug in the formulation and k0, k1 & 
kHC are release rate constants for zero-order, first-order and 
Hixson-Crowell rate equation.
Statistical analysis
All the data were expressed as mean ± SD and the data 
was analyzed by one-way analysis of variance (ANOVA) 
followed by post hoc Tukey test for multiple comparisons 
using Jandel Sigma Stat statistical software, version 2.0. 
In all the analysis p<0.05 was considered as statistically 
significant.
RESULTS AND DISCUSSION
All the CPs prepared was found to be fine and free flowing 
powders. Percentage yield ranged from 87.2 to 92.5% 
(Table 1). Low coefficient of variance (CV) values (< 1.0 
%) in percentage yield indicates the reproducibility of the 
technique employed for the preparation of CPs. Average 
particle size was found to be within the range of 51.53 µm 
to 63.17µm (Table 1). This narrow range of particle size 
was satisfactory from the point of improving the aqueous 
solubility. 
The wetting time ranged from 22.11 to 23.32 sec .The 
maximum wetting time was observed with AF-PVP-CP1 
(23.32 sec). The percentage entrapment of the drug in CPs 
was found to be approximately nearer to the theoretical 
values. Low value for CV (<1.0) indicates uniformity of 
drug content in the product. The obtained results implied 
that the drug remained stable during preparation.
hygroscopic Studies 
The hygroscopicity of binary system containing AF-PVP 
(1:2-AF-PVP-CP3) was found to be more in comparison 
to other under ambient as well as saturation humidity 
conditions. Similar results were reported by Sethia and 
Squilante9 with carbamazepine. At saturation humidity 
conditions the weight gain was higher, compared to 
ambient conditions. 
Scanning Electron Microscopy 
AF appeared as irregular shaped crystals. The original 
morphology of all other binary systems (CPs) had 
disappeared and it was not possible to differentiate between 
the two components. All the binary systems appeared as 
agglomerates exhibiting the presence of a homogeneous 
solid phase of amorphous nature. Existence of a single 
phase is also responsible for the enhanced drug dissolution 
in comparison to pure AF (Figure 1).
Carrier Product Drug : carrier Percent yield
Particle size 
range (µm)
Average particle 
size (µm)
Drug content 
(mg)
Percent drug 
content
Wetting 
Time (sec)
PVP
AF-PVP-CP3 1 : 2 87.2 (0.79) 6.3-152.4 63.11(0.91) 30.4 (33)*
95.7
(0.78)
22.11
(0.22)
AF-PVP-CP 2 1 : 1 91.7 (0.83) 7.3-133.9 51.53(0.92) 44.7 (50)*
96.8
(0.94)
22.16
(0.19)
AF-PVP-CP1 1 : 0.5 92.5 (0.77) 6.1-153.9 63.17(0.89) 67.2 (66.7)*
98.8
(0.91)
23.32
(0.27)
Table 1. Physical characteristics of coprecipitates of aceclofenac.
Values in parenthesis indicates the standard deviation (n=3) and values given in the parenthesis marked with * indicates theoretical values of drug 
content.
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Figure 1. Scanning electron photomicrographs of aceclofenac (A); aceclofenac-PVP (1:2) coprecipitate (B).
Fourier Transformed Infrared Spectroscopic Studies
All the characteristic bands of AF were observed in the 
binary mixtures. Broadening of bands was observed to a 
large extent. The characteristic bands of PVP were observed 
at 2970, 1452, 1417, 1716 and 1270 cm-1. The FTIR spectra of 
physical mixtures and coprecipitates indicate reduction in 
the intensity of several peaks like O-H (s) and C-H (s). The 
absence of any significant change in the IR spectral pattern 
in the formulations containing the drug and carriers 
indicated the absence of interaction between the drug and 
carriers employed for the solubility enhancement. 
Differential Scanning Calorimetric Studies
The pure AF exhibited endothermic peaks at 152.48°C 
Figure 2. In vitro dissolution 
profile of aceclofenac-PVP 
coprecipitates and their physical 
mixtures in 0.1N hCl, ph 1.2.
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Figure 3. In vitro dissolution 
profile of aceclofenac-PVP 
coprecipitates and their physical 
mixtures in phosphate buffer, 
ph 7.4.
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which represents melting of AF and in accordance with the 
literature value3. Another endothermic peak was observed 
at 102 °C. This broad melting transition is due to water, 
because PVP is very hygroscopic product. 
The DSC curve of AF with various carriers physical mixtures 
show peaks resulting from the superposition of their 
separated component DSC curves. The drug endothermic 
peak was suppressed in the thermograms of the CPs 
suggesting that the drug was able to dissolve partially in 
the carrier to form a solid-solid solution. The appearance 
of low intensity endothermic peak also indicated some of 
the drug still managed to crystallize out from the matrix 
of carrier. In addition, PVP due to its amorphous nature 
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Table 2. Comparison of different 
kinetic models applied on the in 
vitro dissolution profile of selected 
formulations of aceclofenac in 
0.1N hCl, ph 1.2 and phosphate 
buffer, ph 7.4.
also aids in retarding the crystallization of the drug. These 
phenomena could also be attributed to the amorphous 
form of the drug in prepared coprecipitates. 
DSC thermograms indicate the existence of the new 
solid phase and confirm FTIR spectral data concerning 
the presence of AF in an amorphous and homogenously 
dispersed state in carriers employed. No additional or shift 
in endothermic peaks were observed which indicated the 
compatibility between the drug and PVP.
In Vitro Release Studies 
In, 0.1N HCl (pH 1.2) and phosphate buffer (pH 7.4), the 
physical mixtures and CPs with all drug: carrier ratios 
exhibited faster dissolution rates than that of pure AF at 
all time points (Figure 2 and 3). The dissolution rate of CPs 
was faster as compared to their corresponding physical 
mixtures at all the time intervals. With the increase in 
the proportion of carrier, rate of dissolution of CPs also 
increases. The order of dissolution shown by the CPs was 
found to be 1:2 > 1:1 > 1:0.5. 
All the AF formulations showed a better dissolution 
profile in phosphate buffer, pH 7.4 in comparison to 0.1N 
HCl, pH 1.2. Similar results were reported by Soni et al.10 
in their saturation solubility studies of AF carried out in 
different dissolution media. Furthermore, this may be 
due to the weakly acidic nature of AF. With reference to 
pH-solubility profile, the dissolution rate of AF has been 
shown to increase on increasing pH of the medium11. This 
supports higher drug release in phosphate buffer, pH 7.4 
in the present study.
Among all the coprecipitates, AF-PVP-CP3 showed the 
maximum dissolution in 0.1N HCl, pH 1.2 (67.7±0.96%) 
and phosphate buffer pH 7.4 (78.2±1.30%) respectively. 
Due to the hydrophilic nature, PVP enhances the wetting 
of hydrophobic drugs in CPs. Since, wetting is prerequisite 
for dissolution, this effect contributed to the faster drug 
release as reported by Simonelli et al12. 
Another mechanism for this preferential enhancement of 
dissolution rate from CPs may be due to the formation 
of a eutectic mixture, or a solid solution. Enhancement 
of dissolution rate from CPs can also be attributed to the 
amorphization of drug and the particle size reduction. The 
particle size reduction results in increased surface area 
available and thus, acceleration of dissolution. In CPs , 
the presence of the water soluble carrier (PVP) results in 
improvement of wetting characteristics of poorly soluble 
drug like AF.
Kinetic Analysis of Drug Release 
The release of drug from all formulations was observed to 
follow the first order release kinetics (Table 2) and have 
shown the maximum dissolution efficiency with AF-PVP-
CP3in both 0.1N HCl, pH 1.2 and phosphate buffer, pH 7.4 
(Table 3). AF-PVP-CP3 showed significantly higher release 
as compared to other formulations (P<0.05).
Formulation Regression equations
Zero order First order Higuchi Hixson Crowell
0.1N HCl, 
pH 1.2
AF-PVP-
CP3 (1:2)
y = -0.5337t + 85.353
R² = 0.8630
y = -0.0041t + 1.9393
R² = 0.9426
y = 6.7205√t - 0.3088
R² = 0.9704
y = 0.012x + 0.2247
R² = 0.9194
Phosphate 
buffer, pH 
7.4
AF-PVP-
CP3 (1:2)
y = -0.595t + 79.886
R² = 0.8343
y = -0.0055t + 1.9153
R² = 0.9445
y = 7.5872√t + 2.8538
R² = 0.9618
y = 0.015x + 0.3155
R² = 0.9139
Table 3. Dissolution parameters of aceclofenac coprecipitates
Sample DP15 DS60
AF 8.12±0.91 43.12
0.1 N HCl, pH 1.2
AF-PVP-CP1 22.01±0.12 51.23
AF-PVP-CP2 32.11±1.21 63.21
AF-PVP-CP3 38.12±0.34 65.32
Phosphate buffer, pH 7.4
AF-PVP-CP1 29.23±1.23 58.34
AF-PVP-CP2 30.01±1.21 59.12
AF-PVP-CP3 39.11±1.34 83.44
DP15= Percent drug dissolved in 15 min; DS60= Dissolution efficiency at t=60 min (calculated from the area under the dissolution curve at t=60 
min and expressed as % of the area of the rectangle described by 100% dissolution in the same time). Each value is the determination of three 
values.
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CONCLUSION
This study clearly shows that addition of hydrophillic 
carrier like PVP to aceclofenac improves its dissolution rate. 
DSC thermograms of physical mixture and coprecipitates 
indicated complete miscibility of the drug in melted carrier. 
Amorphous nature of the drug in coprecipitates was 
confirmed by scanning electron microscopy and a decrease 
in enthalpy of drug melting in coprecipitates compared to 
the pure drug. Results from FT-IR spectroscopy concluded 
that there was no well-defined interaction between 
aceclofenac and carriers employed in the preparation of 
coprecipitates. The coprecipitates of aceclofenac with PVP 
lend an ample credence for better therapeutic efficacy.
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